Antivirals Market to 2017 - Increased Uptake of High Priced Combination Drugs will Offset the Impact of Generics in the HIV Therapeutics Market Market, Trends, Share, Size Research Report

Home
Pharmaceutical
Antivirals Market to 2017 - Increased Uptake of High Priced Combination Drugs will Offset the Impact of Generics in the HIV Therapeutics Market

Antivirals Market to 2017 - Increased Uptake of High Priced Combination Drugs will Offset the Impact of Generics in the HIV Therapeutics Market

Publisher Name » GBI Research

Published Date » 2012-04-20

GBI Research, the leading business intelligence provider, has released its latest research Antivirals Market to 2017 - Increased Uptake of High Priced Combination Drugs will Offset the Impact of Generics in the HIV Therapeutics Market, which essentially provides insights into antivirals therapeutics sales forecasts until 2017. The report covers the key geographies of the US, the top five countries in the European region and Japan. Insights into the antiviral research and development pipeline and the potential future blockbusters by 2017 are included. The report provides an in-depth analysis of HIV, hepatitis, herpes and influenza therapeutic indications, and includes market forecasts and treatment usage patterns for these four therapeutic indications. The report also explores the competitive landscape, including benchmarking for the top companies in the market. Finally, a key trend analysis for mergers and acquisitions and licensing agreements involving antiviral therapies is also presented.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Researchs team of industry experts.

The global Antivirals market shows a moderate growth in the pharmaceutical market and is expected to increase further due to increase in the diseased population, increase in awareness level and launch of new drugs with better efficacy. Some major patent expiries are expected during the forecast period, such as for Sustiva, Combivir, Tenofovir, Telbivudine, Tamiflu and Relenza (by 2017). The patent expiries of these blockbuster drugs will trigger generic competition in the antivirals therapeutics market, making it more competitive. The late stage pipeline drugs such as Rilpivirine, Vicriviroc, Elvitegravir, Inavir and Rapiacta are expected to enter the market, which will positively impact the market.

In 2010, the global antivirals market was estimated to be worth $22.1 billion and is expected to reach revenues of approximately $30.1 billion by 2017 at a CAGR of 4.5% between 2010 and 2017. Overall antiviral market is driven by Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS) therapeutic sales which accounted for 61% of the market 2010. The Research and Development (R&D) pipeline appears moderately strong with 483 molecules, 33% of which are in Phase II.

Scope

Data and analysis on HIV, Hepatitis, Herpes and Influenza therapeutics market in the leading geographies of the world the US, the UK, Germany, France, Italy, Spain, and Japan.
Annualized market data for the antivirals therapeutics market from 2002 to 2010 with forecasts to 2017.Market Data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.
Key drivers and restraints that have had a significant impact on the market.
Competitive landscape of the global antivirals therapeutics market including top companies benchmarking. The key companies studied in this report are Gilead, Merck, GlaxoSmithKline, Roche and Bristol Myers Squibb.
Key M&A activities and licensing agreements that have taken place in the global antivirals market.

Reasons to buy

Build effective strategies to launch their pipeline products by identifying potential geographies.
Exploit in-licensing and out-licensing opportunities by identifying products that might probably fill their portfolio gaps.
Align your product portfolio to the markets with high growth potential.
Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with increased efficiency and better safety profiles.
Develop key strategic initiatives by understanding the key focus areas of leading companies.

Table of Contents

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 9

2 Antivirals Market to 2017 - Introduction 11
2.1 Introduction 11
2.2 GBI Research Report Guidance 11

3 Antivirals Market to 2017 - Market Overview 12
3.1 Market Forecasts 12
3.1.1 Revenue 12
3.1.2 Global Branded vs Generic Market Share 14
3.1.3 Annual Cost of Therapy 15
3.1.4 Treatment Usage Patterns 16
3.2 Drivers and Restraints for the Global Antivirals Therapeutics Market 18
3.2.1 Market Drivers 18
3.2.2 Market Restraints 19

4 Antivirals Market to 2017 - Geographical Landscape 20
4.1 Revenue Analysis by Geography 20
4.2 The US 22
4.2.1 Revenue 22
4.2.2 Annual Cost of Therapy 23
4.2.3 Treatment Usage Patterns 24
4.3 Top Five Countries of Europe 26
4.3.1 Revenue 26
4.3.2 Annual Cost of Therapy 27
4.3.3 Treatment Usage Patterns 28
4.4 Japan 30
4.4.1 Revenue 30
4.4.2 Annual Cost of Therapy 31
4.4.3 Treatment Usage Patterns 32

5 Antivirals Market to 2017 - Therapeutic Landscape 34
5.1 HIV/AIDS Therapeutics Market Forecasts 34
5.1.1 Introduction 34
5.1.2 Revenue 36
5.1.3 Branded vs Generic Market Share 38
5.1.4 Revenue Analysis by Country 39
5.1.5 Annual Cost of Therapy 41
5.1.6 Treatment Usage Patterns 42
5.2 Drivers and Restraints for the Global HIV/AIDS Therapeutics Market 48
5.2.1 Market Drivers 48
5.2.2 Market Restraints 50
5.3 Hepatitis Therapeutics Market Forecasts 52
5.3.1 Introduction 52
5.3.2 Revenue 55
5.3.3 Branded vs Generic Market Share 57
5.3.4 Revenue Analysis by Country 58
5.3.5 Annual Cost of Therapy 60
5.3.6 Treatment Usage Patterns 61
5.4 Drivers and Restraints for the Global Hepatitis Therapeutics Market 63
5.4.1 Market Drivers 63
5.4.2 Market Restraints 64
5.5 Herpes Therapeutics Market Forecasts 64
5.5.1 Introduction 64
5.5.2 Revenue 67
5.5.3 Branded vs Generic Market Share 68
5.5.4 Revenue Analysis by Country 69
5.5.5 Annual Cost of Therapy 71
5.5.6 Treatment Usage Pattern 72
5.6 Drivers and Restraints for the Global Herpes Therapeutics Market 73
5.6.1 Market Drivers 73
5.6.2 Market Restraints 74
5.7 Influenza Therapeutics Market Forecasts 75
5.7.1 Introduction 75
5.7.2 Revenue 77
5.7.3 Branded vs Generic Market Share 78
5.7.4 Revenue Analysis by Country 79
5.7.5 Annual Cost of Therapy 80
5.7.6 Treatment Usage Patterns 81
5.8 Drivers and Restraints for the Global Influenza Therapeutics Market 83
5.8.1 Market Drivers 83
5.8.2 Market Restraints 83

6 Antivirals Market to 2017 - Pipeline Analysis 84
6.1 R&D Pipeline by Phase 84
6.2 R&D Pipeline by Indication 85
6.3 R&D Pipeline - HIV/AIDS 86
6.3.1 Overview 86
6.3.2 Pipeline by Clinical Phase of Development 87
6.4 Promising Molecules under Development - HIV/AIDS 92
6.4.1 Quad 92
6.4.2 Elvitegravir 92
6.4.3 GSK1349572 93
6.5 R&D Pipeline - Hepatitis 94
6.5.1 Overview 94
6.5.2 R&D Pipeline by Indications 95
6.6 Promising Molecules under Development - Vaccines for Hepatitis B 104
6.6.1 Heplisav 104
6.6.2 Spi-VEC 105
6.7 Promising Molecules under Development - Therapeutics for Hepatitis B 105
6.7.1 Entecavir plus Adefovir Combination Therapy 105
6.7.2 Tenofovir plus Emtricitabine Combination Therapy 106
6.7.3 Pegylated Interferon Alfa-2a + Adefovir 106
6.8 Promising Molecules under Development - Therapeutics for Hepatitis C 107
6.8.1 Zalbin (albinterferon alfa-2b, Joulferon) 107
6.8.2 RG 7128 108
6.9 R&D Pipeline - Herpes 109
6.9.1 Overview 109
6.9.2 R&D Pipeline by Indication 110
6.9.3 Herpes Simplex - Pipeline by Clinical Phase of Development 110
6.9.4 Herpes Zoster - Pipeline by Clinical Phase of Development 112
6.10 Promising Molecules under Development - Herpes 113
6.10.1 BA-021 113
6.10.2 NB-001 113
6.10.3 ARYS-01 114
6.10.4 GSK 1437173A 115
6.10.5 V212 115
6.11 R&D Pipeline - Influenza 116
6.11.1 Overview 116
6.11.2 Pipeline by Clinical Phase of Development 117
6.12 Promising Molecules under Development - Influenza 120
6.12.1 S-021812 120
6.12.2 CS-8958 121
6.12.3 T-705 121

7 Antivirals Market to 2017: Competitive Landscape 122
7.1 Profiles of Major Companies 122
7.1.1 GlaxoSmithKline (GSK) 122
7.1.2 Merck 123
7.1.3 F. Hoffmann-La Roche Ltd. 124
7.1.4 Gilead Sciences, Inc 125
7.1.5 Bristol-Myers Squibb (BMS) 126

8 Antivirals Market to 2017 - Strategic Consolidations 127
8.1 Mergers and Acquisitions 127
8.1.1 Segmentation by Indication 127
8.1.2 Segmentation by Geography 128
8.1.3 Segmentation by Deal Value 129
8.1.4 Major Mergers and Acquisitions Deals 130
8.2 Licensing Deals 132
8.2.1 Segmentation by Indication 132
8.2.2 Segmentation by Geography 133
8.2.3 Segmentation by Deal Value 134
8.2.4 Major Licensing Deals 135

9 Antivirals Market to 2017 - Appendix 139
9.1 Market Definitions 139
9.2 Abbreviations 139
9.3 Research Methodology 141
9.3.1 Coverage 141
9.3.2 Secondary Research 141
9.3.3 Primary Research 141
9.4 Research Methodology 142
9.4.1 Therapeutic Landscape 142
9.4.2 Geographical Landscape 145
9.4.3 Pipeline Analysis 145
9.4.4 Competitive Landscape 145
9.5 Expert Panel Validation 145
9.6 Contact Us 145
9.7 Disclaimer 145
9.8 Sources 146

List of Tables

Table 1: Antivirals Market, Global, Revenue ($bn), 2002-2010 12
Table 2: Antivirals Market, Global, Revenue Forecasts ($bn), 2010-2017 12
Table 3: Antivirals Market, Global, Market Share by Indication, (%), 2010 13
Table 4: Antivirals Market, Global, Annual Cost of Therapy ($), 2002-2010 15
Table 5: Antivirals Market, Global, Annual Cost of Therapy ($), 2010-2017 15
Table 6: Antivirals Market, Global, Treatment Usage Patterns (Millions), 2002-2010 16
Table 7: Antivirals Market, Global, Treatment Usage Patterns (Millions), 2010-2017 17
Table 8: Antivirals Market, Global, Revenue by Country ($m), 2002-2010 20
Table 9: Antivirals Market, Global, Revenue Forecasts by Country ($m), 2010-2017 21
Table 10: Antivirals Market, The US, Revenue ($m), 2002-2010 22
Table 11: Antivirals Market, The US, Revenue Forecasts ($m), 2010-2017 22
Table 12: Antivirals Market, The US, Annual Cost of Therapy ($), 2002-2010 23
Table 13: Antivirals Market, The US, Annual Cost of Therapy ($), 2010-2017 23
Table 14: Antivirals Market, The US, Treatment Usage Patterns (Millions), 2002-2010 24
Table 15: Antivirals Market, The US, Treatment Usage Patterns (Millions), 2010-2017 25
Table 16: Antivirals Market, Top Five Countries of Europe, Revenue ($m), 2002-2010 26
Table 17: Antivirals Market, Top Five Countries of Europe, Revenue Forecasts ($m), 2010-2017 26
Table 18: Antivirals Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2002-2010 27
Table 19: Antivirals Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2010-2017 27
Table 20: Antivirals Market, Top Five Countries of Europe, Treatment Usage Patterns (Millions), 2002-2010 28
Table 21: Antivirals Market, Top Five Countries of Europe, Treatment Usage Patterns (Millions), 2010-2017 29
Table 22: Antivirals Market, Japan, Revenue ($m), 2002-2010 30
Table 23: Antivirals Market, Japan, Revenue Forecasts ($m), 2010-2017 30
Table 24: Antivirals Market, Japan, Annual Cost of Therapy ($), 2002-2010 31
Table 25: Antivirals Market, Japan, Annual Cost of Therapy ($), 2010-2017 31
Table 26: Antivirals Market, Japan, Treatment Usage Patterns (Millions), 2002-2010 32
Table 27: Antivirals Market, Japan, Treatment Usage Patterns (Millions), 2010-2017 33
Table 28: HIV/AIDS Therapeutics Market, Global, Revenue ($m), 20022010 36
Table 29: HIV/AIDS Therapeutics Market, Global, Revenue Forecasts ($m), 20102017 36
Table 30: HIV/AIDS Therapeutics Market, Global, Geographical Distribution of Revenue ($m), 20022010 39
Table 31: HIV/AIDS Therapeutics Market, Global, Geographical Distribution of Revenue ($m), 20102017 40
Table 32: HIV/AIDS Therapeutics Market, Global, Annual Cost of Therapy ($), 20022010 41
Table 33: HIV/AIDS Therapeutics Market, Global, Annual Cost of Therapy ($), 20102017 41
Table 34: HIV/AIDS Therapeutics Market, Global, Treatment Usage Patterns (000), 20022010 43
Table 35: HIV/AIDS Therapeutics Market, Global, Treatment Usage Patterns (000), 20102017 43
Table 36: HIV/AIDS Therapeutics Market, Global, Key Drugs Going Off Patent, 20102017 51
Table 37: Hepatitis Therapeutics Market, Global, Revenue ($m), 20022010 55
Table 38: Hepatitis Therapeutics Market, Global, Revenue Forecasts ($m), 20102017 55
Table 39: Hepatitis Therapeutics Market, Global, Revenue by Geography ($m), 20022010 58
Table 40: Hepatitis Therapeutics Market, Global, Revenue Forecasts by Geography ($m), 20102017 59
Table 41: Hepatitis Therapeutics Market, Global, Annual Cost of Therapy ($), 20022010 60
Table 42: Hepatitis Therapeutics Market, Global, Annual Cost of Therapy ($), 20102017 60
Table 43: Hepatitis Therapeutics Market, Global, Treatment Usage Pattern (000s), 20022010 61
Table 44: Hepatitis Therapeutics Market, Global, Treatment Usage Pattern (000s), 20102017 62
Table 45: Herpes Therapeutics Market, Global, Revenue ($bn), 20022010 67
Table 46: Herpes Therapeutics Market, Global, Revenue Forecasts ($bn), 20102017 67
Table 47: Herpes Therapeutics Market, Global, Revenue by Geography ($m), 20022010 69
Table 48: Herpes Therapeutics Market, Global, Revenue Forecasts by Geography ($m), 20102017 70
Table 49: Herpes Market, Global, Annual Cost of Therapy ($), 20022010 71
Table 50: Herpes Market, Global, Annual Cost of Therapy ($), 2010-2017 71
Table 51: Herpes Market, Global, Treatment Usage Patterns (Millions), 20022010 72
Table 52: Herpes Market, Global, Treatment Usage Patterns (Millions), 20102017 72
Table 53: Influenza Therapeutics Market, Global, Revenue ($bn), 20022010 78
Table 54: Influenza Therapeutics Market, Global, Revenue Forecasts ($bn), 20102017 78
Table 55: Influenza Therapeutics Market, Global Revenue by Country ($m), 20022010 79
Table 56: Influenza Therapeutics Market, Global Revenue Forecasts by Country ($m), 20102017 80
Table 57: Influenza Therapeutics Market, Global, Annual Cost of Therapy ($), 20022010 80
Table 58: Influenza Therapeutics Market, Global, Annual Cost of Therapy ($), 20102017 81
Table 59: Influenza Therapeutics Market, Global, Treatment Usage Patterns (Million), 20022010 81
Table 60: Influenza Therapeutics Market, Global, Treatment Usage Patterns (Million), 20102017 82
Table 61: Antivirals Therapeutics Market, Global, Pipeline Molecules by Phase (%), 2011 84
Table 62: Antivirals Therapeutics Market, Global, Pipeline Molecules by Indication (%), 2011 85
Table 63: HIV/AIDS Therapeutics Market, Global, Pipeline Molecules by Phase (%), 2011 86
Table 64: HIV/AIDS Therapeutics Market, Global, Discovery Pipeline Molecules, 2011 87
Table 65: HIV/AIDS Therapeutics Market, Global, Preclinical Pipeline Molecules, 2011 88
Table 66: HIV/AIDS Therapeutics Market, Global, Phase I Pipeline Molecules, 2011 89
Table 67: HIV/AIDS Therapeutics Market, Global, Phase II Pipeline Molecules, 2011 90
Table 68: HIV/AIDS Therapeutics Market, Global, Phase III Pipeline Molecules, 2011 91
Table 69: Hepatitis Therapeutics Market, Global, Pipeline Molecules by Phase (%), 2011 94
Table 70: Hepatitis Market, Global, R&D Pipeline by Indication (%), 2011 95
Table 71: Hepatitis B Therapeutics Market, Global, Pipeline, 2011 96
Table 72: Hepatitis B Vaccines Market, Global, Pipeline, 2011 97
Table 73: Hepatitis C Therapeutics Market, Global, Pipeline, 2011 98
Table 74: Herpes Therapeutics Market, Global, Pipeline Molecules by Phase (%), 2011 109
Table 75: Herpes Market, Global, R&D Pipeline by Indication (%), 2011 110
Table 76: Herpes Simplex Market, Global, Discovery and IND Filed Pipeline Molecules, 2011 110
Table 77: Herpes Simplex Market, Global, Pre-Clinical Pipeline Molecules, 2011 111
Table 78: Herpes Simplex Market, Global, Phase I Pipeline Molecules, 2011 111
Table 79: Herpes Simplex Market, Global, Phase II Pipeline Molecules 2011 111
Table 80: Herpes Simplex Market, Global, Phase III and NDA Filed Pipeline Molecules 2011 112
Table 81: Herpes Zoster Market, Global, Pre-Clinical and Phase II Pipeline Molecules 2011 112
Table 82: Herpes Zoster Market, Global, Phase III Pipeline Molecules 2011 112
Table 83: Influenza Therapeutics Market, Global, Pipeline Molecules by Phase (%), 2011 116
Table 84: Influenza Therapeutics Market, Global, Discovery Pipeline Molecules, 2011 117
Table 85:Influenza Therapeutics Market, Global, Preclinical Pipeline Molecules, 2011 118
Table 86:Influenza Therapeutics Market, Global, Phase I Pipeline Molecules, 2011 119
Table 87:Influenza Therapeutics Market, Global, Phase II Pipeline Molecules, 2011 119
Table 88:Influenza Therapeutics Market, Global, Phase III/NDA filed Pipeline Molecules, 2011 120
Table 89:Antivirals Market, Global, M&A Deals by Indication,2004-2011 127
Table 90:Antivirals Market, Global, M&A Deals by Geography, 2004-2011 128
Table 91:Antivirals Market, Global, M&A Deals by Deal Value, 2004-2011 129
Table 92:Antivirals Market, Global, Licensing Deals by Indication, 2004-2011 132
Table 93:Antivirals Market, Global, Licensing Deals by Geography, 2004-2011 133
Table 94:Antivirals Market, Global, Licensing Deals by Deal Value, 2004-2011 134

List of Figures

Figure 1: Antivirals Market, Global, Revenue Forecasts ($bn), 2002-2017 12
Figure 2: Antivirals Market, Global, Market Share by Indication (%), 2010 13
Figure 3: Antivirals Market, Global, Branded vs Generic Market Share (%), 2010 and 2017 14
Figure 4: Antivirals Market, Global, Annual Cost of Therapy ($), 2002-2017 15
Figure 5: Antivirals Market, Global, Treatment Usage Patterns (Millions), 2002-2017 16
Figure 6: Antivirals Market, Global, Market Drivers and Restraints, 2010 18
Figure 7: Antivirals Market, Global, Revenue Forecasts by Country ($m), 2002-2017 20
Figure 8: Antivirals Market, The US, Revenue Forecasts ($m), 2002-2017 22
Figure 9: Antivirals Market, The US, Annual Cost of Therapy ($), 2002-2017 23
Figure 10: Antivirals Market, The US, Treatment Usage Patterns (Millions), 2002-2017 24
Figure 11: Antivirals Market, Top Five Countries of Europe, Revenue Forecasts ($m), 2002-2017 26
Figure 12: Antivirals Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2002-2017 27
Figure 13: Antivirals Market, Top Five Countries of Europe, Treatment Usage Patterns (Millions), 2002-2017 28
Figure 14: Antivirals Market, Japan, Revenue Forecasts ($m), 2002-2017 30
Figure 15: Antivirals Market, Japan, Annual Cost of Therapy ($), 2002-2017 31
Figure 16: Antivirals Market, Japan, Treatment Usage Patterns (Millions), 2002-2017 32
Figure 17: HIV/AIDS Therapeutics Market, Global, HIV/AIDS Treatment Flow Algorithm, 2011 35
Figure 18: HIV/AIDS Therapeutics Market, Global, Revenue Forecasts ($m), 20022017 36
Figure 19: HIV/AIDS Therapeutics Market, Global, Branded vs Generic Market Share (%), 2010 and 2017 38
Figure 20: HIV/AIDS Therapeutics Market, Global, Geographical Distribution of Revenue ($m), 20022017 39
Figure 21: HIV/AIDS Therapeutics Market, Global, Annual Cost of Therapy ($), 20022017 41
Figure 22: HIV/AIDS Therapeutics Market, Global, Treatment Usage Patterns, 20022017 42
Figure 23: HIV/AIDS Therapeutics Market, Global, Diseased Population, 20022017 44
Figure 24: HIV/AIDS Therapeutics Market, Global, Treatment Seeking Population, 20022017 45
Figure 25: HIV/AIDS Therapeutics Market, Global, Diagnosis Population, 20022017 46
Figure 26: HIV/AIDS Therapeutics Market, Global, Prescription Population, 20022017 47
Figure 27: HIV/AIDS Therapeutics Market, Global, Market Drivers and Restraints, 2010 48
Figure 28: Hepatitis Market, Global, Hepatitis B-Genotypes Based on Geographic Origins 53
Figure 29: Hepatitis Market, Hepatitis Treatment Flow Pathway, 2011 54
Figure 30: Hepatitis Therapeutics Market, Global, Revenue Forecasts ($m), 20022017 55
Figure 31: Hepatitis Therapeutics Market, Global, Branded vs Generic Market Share (%), 2010 and 2017 57
Figure 32: Hepatitis Therapeutics Market, Global, Revenue Forecasts by Geography ($m), 20022017 58
Figure 33: Hepatitis Therapeutics Market, Global, Annual Cost of Therapy ($), 20022017 60
Figure 34: Hepatitis Therapeutics Market, Global, Treatment Usage Patterns (000), 20022017 61
Figure 35: Hepatitis Therapeutics Market, Global, Drivers and Restraints, 2011 63
Figure 36: Herpes Therapeutics Market, Global, Treatment Algorithm 66
Figure 37: Herpes Therapeutics Market, Global, Revenue Forecasts ($bn), 20022017 67
Figure 38: Herpes Therapeutics Market, Global, Branded vs Generic Market Share, 2010 and 2017 68
Figure 39: Herpes Therapeutics Market, Global, Revenue Forecasts by Geography ($m), 20022017 69
Figure 40: Herpes Market, Global, Annual Cost of Therapy ($), 20022017 71
Figure 41: Herpes Market, Global, Treatment Usage Patterns (Millions), 20022017 72
Figure 42: Herpes Therapeutics Market, Global, Drivers and Restraints, 2010 73
Figure 43: Influenza Therapeutics Market, Treatment Flow Algorithm for Influenza, 2011 76
Figure 44: Influenza Therapeutics Market, Global, Revenue Forecasts ($bn), 20022017 77
Figure 45: Influenza Therapeutics Market, Global, Branded vs Generic Market Share (%), 2010 and 2017 78
Figure 46: Influenza Therapeutics Market, Global, Revenue Forecasts by Country ($m), 20022017 79
Figure 47: Influenza Therapeutics Market, Global, Annual Cost of Therapy ($), 20022017 80
Figure 48: Influenza Therapeutics Market, Global, Treatment Usage Patterns (Million), 20022017 81
Figure 49: Influenza Therapeutics Market, Global, Drivers and Restraints, 2010 83
Figure 50: Antivirals Therapeutics Market, Global, Pipeline Molecules by Phase (%), 2011 84
Figure 51: Antivirals Therapeutics Market, Global, Pipeline Molecules by Indication (%), 2011 85
Figure 52: HIV/AIDS Therapeutics Market, Global, Pipeline Molecules by Phase (%), 2011 86
Figure 53: Hepatitis Therapeutics Market, Global, Pipeline Molecules by Phase (%), 2011 94
Figure 54: Hepatitis Market, Global, R&D Pipeline by Indication (%), 2011 95
Figure 55: Herpes Therapeutics Market, Global, Pipeline Molecules by Phase (%), 2011 109
Figure 56: Herpes Market, Global, R&D Pipeline by Indication (%), 2011 110
Figure 57: Influenza Therapeutics Market, Global, Pipeline Molecules by Phase (%), 2011 116
Figure 58: Antivirals Market, GlaxoSmithKline, SWOT Analysis, 2011 122
Figure 59: Antivirals Market, Merck, SWOT Analysis, 2011 123
Figure 60: Antivirals Market, Roche, SWOT Analysis, 2011 124
Figure 61: Antivirals Market, Gilead, SWOT Analysis, 2011 125
Figure 62: Antivirals Market, Bristol-Myers Squibb, SWOT Analysis, 2011 126
Figure 63: Antivirals Market, Global, M&A Deals by Indication (%), 2004-2011 127
Figure 64: Antivirals Market, Global, M&A Deals by Geography (%), 2004-2011 128
Figure 65: Antivirals Market, Global, M&A Deals by Deal Value (%), 2004-2011 129
Figure 66: Antivirals Market, Global, Licensing Deals by Indication (%), 2004-2011 132
Figure 67:Antivirals Market, Global, Licensing Deals by Geography (%), 2004-2011 133
Figure 68:Antivirals Market, Global, Licensing Deals by Deal Value (%), 2004-2011 134
Figure 69: GBI Research Market Forecasting Model 144

Related Reports

Home Healthcare Market - Global Industry Size, Market Share, Trends, Analysis And Forecast, 2012 - 2018

Oct 22, 2012 | By - Transparency Market Research

This report is an effort to identify factors, which will be the driving force behind the home healthcare market and sub-markets in the next few years. The report provides extensive analysis of the industry, current market trends, industry drivers and challenges for better understanding of the market structure. The report has segregated the home healthcare industry in terms of...

Biopharmaceutical Manufacturing in India, China and South Korea - Regulatory Framework, Infrastructure Support and Discovery Funding Create an Environment Conducive to Growth

Oct 1, 2012 | By - GBI Research

Biopharmaceutical Manufacturing in India, China and South Korea Regulatory Framework, Infrastructure Support and Discovery Funding Create an Environment Conducive to Growth GBI Research, the leading business intelligence provider has released its latest research report, Biopharmaceutical Manufacturing in India, China and South Korea Regulatory Framework, Infrastructure Support...

Gastrointestinal Disorders Therapeutics Market to 2018 - Novel Agents Targeting Irritable Bowel Syndrome (IBS), Chronic Constipation (CC) and Ulcerative Colitis (UC) to Reinvigorate the Market

Nov 1, 2012 | By - GBI Research

Gastrointestinal Disorders Therapeutics Market to 2018 Novel Agents Targeting Irritable Bowel Syndrome (IBS), Chronic Constipation (CC) and Ulcerative Colitis (UC) to Reinvigorate the Market GBI Research, the leading business intelligence provider, has released its latest research, Gastrointestinal Disorders Therapeutics Market to 2018 Novel Agents Targeting Irritable...

Biodefense Industry - Market to Benefit from Federal Funding such as the BIO EDEP Fund to Support Security Plans

Sep 30, 2012 | By - GBI Research

Biodefense Industry Market to Benefit from Federal Funding such as the BIO EDEP Fund to Support Security Plans GBI Research, the leading business intelligence provider has released its latest research report, Biodefense Industry Market to Benefit from Federal Funding such as the BIO EDEP Fund to Support Security Plans. The report focuses on the key insights into the biodefense...

e-Clinical Trial Solutions Market to 2018 - Growing Complexity of Clinical Trials and Increased Focus on Accuracy and Efficiency Drive Trial Sponsors to Adopt Novel Technologies

Jul 31, 2012 | By - GBI Research

GBI Research, the leading business intelligence provider, has released its latest research, e-Clinical Trial Solutions Market to 2018 Growing Complexity of Clinical Trials and Increased Focus on Accuracy and Efficiency Drive Trial Sponsors to Adopt Novel Technologies, which provides key data and analysis of the major factors affecting the market for eClinical trial solutions in the...

Upcoming Reports:

Pulmonary Arterial Hypertension (PAH) Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, And Forecast, 2012 - 2018

By - Transparency Market Research

Pulmonary arterial hypertension (PAH), a type of pulmonary hypertension results from high blood pressure associated with arteries of the lungs. In PAH, the arteries of the lungs (pulmonary arteries) become narrower than their actual size, giving rise to high blood pressure in the arteries of the lungs thus putting pressure on the right ventricle of the heart. Some of the main causes of occurrences of this disease are bad habits such as stressful lifestyle, intake of certain medicines etc. There is no exact treatment available for PAH but existing medication may help treat the symptoms....

Bus Rapid Transit Systems Market - Global Forecast, Market Share, Size, Growth And Industry Analysis, 2011 - 2017

By - Transparency Market Research

The Bus Rapid Transit Systems (BRT) is the upcoming public transportation system providing efficient, cost effective, safer and faster transport than the traditional bus service. The deployment of BRT requires upgradation of the existing infrastructure to help improvise its functionality. In developed countries it is known as busway while in other countries it is called quality bus. The world’s first BRT was Rede Integrada de Transporte deployed in Brazil, 1974. The BRT has certain unique features like dedicated roadways or right side bus way only. Certain...

Platform-As-A-Service Market - Global Industry Size, Share, Trends, Analysis, And Forecast, 2012 - 2018

By - Transparency Market Research

PaaS (Platform as a Service) is a service that provides a cloud computing platform and solution stack services. PaaS, the service model of cloud, is used by consumers for developing software by using tools or libraries from the provider. Consumers can also control the configuration settings and software deployment. Platform as a service model helps in the employment of applications, eliminating the cost and complexity of buying and managing the necessary hardware and software. PaaS is the major component of the new cloud computing service where developers are allowed to...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)

Tel: +1-518-618-1030
Email: sales@researchmoz.com

Select License type:

Share this report

Latest Reports

Sep 14, 2012

The healthcare Industry in the United States works as a separate entity and many of the healthcare services are privately owned and operated. Healthcare has always been a topic of debate for the U.S. government because policy makers argue that the system is not delivering value for money services. In fact government is spending twice as much on life expectancy and infant mortality rate...

Now At-Home TB Diagnosis Looks Possible

Sep 14, 2012

According to a recent research published in Nature Chemistry, scientists have revealed that a certain sensitive fluorescent molecule is capable of efficiently and quickly tracing TB (tuberculosis) bacteria from the sputum samples. The year 2010 registered approximately 4000 deaths per day because of TB. TB diagnosis takes a few weeks and the disease being contagious puts others at...

China Economy Gets USD 157 Billion Stimulus with Sanction for 60 Infrastructure Projects

Sep 14, 2012

Seen as a much required economical stimulus to revive the economy stuck in the worst slowdown in the past three years, China has approved 60 different infrastructure projects valued at more than USD 150 billion. Immediately after the official confirmation of the decision, stocks of major industries such as cement and steel have seen a rise on hopes generated by plans to build ports, highways,...

Battling against flu, vaccination necessary for health workers

Sep 14, 2012

To battle against flu this season, health officials have tightened their resolve to get more health care workers vaccinated. Flu is a disease that transfers from one to another. Keeping this in mind health officials want every worker in the health care department to get vaccinated. By doing this, it will lessen the chances of others getting affected by this disease. Health officials...

Japan to Cut Import Duties on Indian Generic Drugs Imports

Sep 14, 2012

The 44th ASEAN Economic Ministers Meeting held last week in Cambodia has certainly brought good news for the Indian Pharmaceuticals industry. During the meeting on the sidelines of the 44th ASEAN Economic Ministers Meet, Indian Commerce and Industry Minister Anand Sharma brought up the issue with his Japanese counterpart Yukio Edano. Yukio Edano is the minister of economy, trade and Industry...